Kerry David Fisher

List of Publications by Year
in descending order

73 papers	3,026 citations	185998 28 h-index	182168 51 g-index
73 all docs	73 docs citations	73 times ranked	3463 citing authors

#	Article	IF	Citations
1	In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nature Biotechnology, 2015, 33, 1201-1210.	9.4	362
2	Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009, 113, 1909-1918.	0.6	183
3	Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. PLoS ONE, 2008, 3, e2409.	1.1	158
4	Decreased Binding to Proteins and Cells of Polymeric Gene Delivery Vectors Surface Modified with a Multivalent Hydrophilic Polymer and Retargeting through Attachment of Transferrin. Journal of Biological Chemistry, 2000, 275, 3793-3802.	1.6	148
5	Adenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery. Molecular Therapy, 2006, 14, 118-128.	3.7	138
6	An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. Cancer Research, 2018, 78, 6852-6865.	0.4	123
7	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113
8	Oncolytic adenovirus expressing bispecific antibody targets Tâ€cell cytotoxicity in cancer biopsies. EMBO Molecular Medicine, 2017, 9, 1067-1087.	3.3	104
9	Oncolytic viruses: finally delivering. British Journal of Cancer, 2016, 114, 357-361.	2.9	95
10	Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor. Molecular Therapy, 2008, 16, 244-251.	3.7	81
11	HPMA copolymers for masking and retargeting of therapeutic virusesâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 240-245.	6.6	78
12	Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes. Journal of Controlled Release, 2014, 178, 101-107.	4.8	73
13	Deregulation of HLA-I in cancer and its central importance for immunotherapy. , 2021, 9, e002899.		73
14	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). , 2019, 7, 20.		68
15	Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Therapy, 2002, 9, 543-552.	2.2	58
16	Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. , 2019, 7, 320.		58
17	Solid Tumor Immunotherapy with T Cell Engagerâ€Armed Oncolytic Viruses. Macromolecular Bioscience, 2018, 18, 1700187.	2.1	56
18	Coating of adenoâ€associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. Journal of Gene Medicine, 2008, 10, 400-411.	1.4	55

#	Article	IF	Citations
19	Retargeting polymerâ€coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. Journal of Gene Medicine, 2008, 10, 280-289.	1.4	52
20	Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. Journal of Controlled Release, 2009, 135, 152-158.	4.8	52
21	Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. Journal of Controlled Release, 2011, 156, 381-389.	4.8	49
22	Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Current Opinion in Molecular Therapeutics, 2006, 8, 301-13.	2.8	47
23	Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. Journal of Drug Targeting, 2007, 15, 546-551.	2.1	45
24	Cancer gene therapy with targeted adenoviruses. Expert Opinion on Drug Delivery, 2008, 5, 1231-1240.	2.4	43
25	Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer. Angewandte Chemie - International Edition, 2005, 44, 1057-1061.	7.2	41
26	Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular Therapy - Oncolytics, 2017, 5, 62-74.	2.0	40
27	Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting, 2005, 13, 39-51.	2.1	37
28	Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer. Human Gene Therapy, 2009, 20, 239-251.	1.4	37
29	Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators. Molecular Therapy - Oncolytics, 2017, 4, 18-30.	2.0	37
30	Recombinant viral vaccines for cancer. Trends in Molecular Medicine, 2012, 18, 564-574.	3.5	35
31	Combining Oncolytic Adenovirus with Radiationâ€”A Paradigm for the Future of Radiosensitization. Frontiers in Oncology, 2017, 7, 153.	1.3	32
32	Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy. Human Gene Therapy, 2010, 21, 795-805.	1.4	29
33	Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. Journal of Controlled Release, 2011, 150, 196-203.	4.8	29
34	Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth. Molecular Therapy, 2016, 24, 796-804.	3.7	29
35	NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. Molecular Therapy - Oncolytics, 2020, 16, 289-301.	2.0	29
36	Use of a Phage Display Library to Identify Oligopeptides Binding to the Lumenal Surface of Polarized Endothelium byEx VivoPerfusion of Human Umbilical Veins. Journal of Drug Targeting, 2003, 11, 53-59.	2.1	25

#	Article	IF	Citations
37	Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine, 2012, 7, 1683-1695.	1.7	23
38	Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS ONE, 2017, 12, e0177810.	1.1	23
39	Quantification of siRNA using competitive qPCR. Nucleic Acids Research, 2009, 37, e4-e4.	6.5	19
40	OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution. Molecular Therapy - Oncolytics, 2017, 4, 55-66.	2.0	17
41	Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity In Vitro and In Vivo. Bioconjugate Chemistry, 2019, 30, 1244-1257.	1.8	17
42	Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. Virology, 2017, 505, 162-171.	1.1	16
43	Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirusÂin murine cancer cells. , 2018, 6, 55.		16
44	Making Oncolytic Virotherapy a Clinical Reality: The European Contribution. Human Gene Therapy, 2017, 28, 1033-1046.	1.4	14
45	A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology, 2020, 15, 151.	1.2	14
46	Turbidometric analysis of polyelectrolyte complexes formed between poly(l-lysine) and DNA. Colloids and Surfaces B: Biointerfaces, 1999, 16, 253-260.	2.5	13
47	Virotherapy â€“ cancer targeted pharmacology. Drug Discovery Today, 2012, 17, 215-220.	3.2	13
48	External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. Cancers, 2020, 12, 798.	1.7	11
49	E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-Î±-activated human umbilical vein endothelial cells. Journal of Drug Targeting, 2011, 19, 690-700.	2.1	10
50	Macrophages and their interactions with oncolytic viruses. Current Opinion in Pharmacology, 2015, 24, 23-29.	1.7	10
51	DYNAMICS OF POLYDISPERSE IRREVERSIBLE ADSORPTION: A PHARMACOLOGICAL EXAMPLE. Mathematical Models and Methods in Applied Sciences, 2007, 17, 759-781.	1.7	9
52	Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics. Molecular Therapy - Nucleic Acids, 2013, 2, e133.	2.3	8
53	A PTENtial cause for the selectivity of oncolytic viruses?. Nature Immunology, 2016, 17, 225-226.	7.0	8
54	Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Molecular Therapy - Oncolytics, 2021, 21, 47-61.	2.0	8

#	Article	IF	Citations
55	Pâ€selectin dependent targeting to inflamed endothelium of recombinant Pâ€selectin glycoprotein ligandâ€1 immunoglobulin chimeraâ€coated poly[Nâ€(2â€hydroxypropyl) methacrylamide]â€DNA polyplexes in vivo visualised by intravital microscopy. Journal of Gene Medicine, 2009, 11, 326-334.	1.4	7
56	In vitro evaluation of a â€˜stealthâ€™ adenoviral vector for targeted gene delivery to adult mammalian neurones. Journal of Gene Medicine, 2009, 11, 335-344.	1.4	7
57	Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of Drug Targeting, 2007, 15, 311-319.	2.1	6
58	Adenovirus: Teaching an Old Dog New Tricks. Human Gene Therapy, 2011, 22, 1041-1042.	1.4	6
59	Improved In Vitro Human Tumor Models for Cancer Gene Therapy. Human Gene Therapy, 2015, 26, 249-256.	1.4	6
60	Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers, 2021, 13, 719.	1.7	6
61	Preclinical Screening of Gene Therapy in Human Tissues. Human Gene Therapy, 2009, 20, 291-292.	1.4	5
62	The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy. Cytokine and Growth Factor Reviews, 2020, 56, 115-123.	3.2	5
63	A Sensitive Assay System for the Determination of Poly(L-Lysine) Concentration Using Turbidometry. Journal of Bioactive and Compatible Polymers, 1999, 14, 122-136.	0.8	4
64	Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses. Molecular Therapy, 2016, 24, 204-205.	3.7	4
65	Establishment of a positive-readout reporter system for siRNAs. Journal of Rnai and Gene Silencing, 2009, 5, 331-8.	1.2	4
66	A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I.. Journal of Clinical Oncology, 2016, 34, 5543-5543.	0.8	2
67	Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer. Angewandte Chemie, 2005, 117, 1081-1085.	1.6	1
68	"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours. , 2014, 2, .		1
69	Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Human Gene Therapy, 2008, .	1.4	1
70	Cover Picture: Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer (Angew.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	7.2	0
71	Titelbild: Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer (Angew. Chem.) Tj ETQq1 1 0.784314 rgBT /Overlo	1.6	0
72	Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus. Human Gene Therapy, 2008, .	1.4	0

#	Article	IF	Citations
73	Abstract 295: Delivery of checkpoint inhibitor antibodies and other therapeutics directly to tumors by encoding them within the oncolytic adenovirus enadenotucirev. , 2015, , .		0